Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cigna Corp (NY:CI)

308.64 -3.36 (-1.08%)
Streaming Delayed Price Updated: 11:42 AM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cigna Corp

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth
Healthcare stocks offer wealth to investors through a mix of steady performance, growth and income not to be overlooked. 
Via InvestorPlace
3 Healthcare Stocks to Buy at a 52-Week Low in July
At their 52-week lows, these undervalued healthcare stocks present a favorable return supported by healthcare spending tailwinds. 
Via InvestorPlace
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Don't overlook NYSE:CI—a stock with solid growth prospects and a reasonable valuation.
THE CIGNA GROUP (NYSE:CI) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
2 Beaten-Down Dividend Stocks With Ultra-High Yields Above 9%: Are They Bargains Now?
Find out if the huge yields these pressured dividend payers offer could be worth the risk. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Cigna Group Stock In The Last 20 Years
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,400 Today
Via Benzinga
Looking Into Cigna Group's Recent Short Interest
Via Benzinga
Decoding Cigna Group's Options Activity: What's the Big Picture?
Via Benzinga
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
BofA Downgrades Elevance Health On Medicaid Pressure And Lowered Peer Valuations
Elevance Health reports Q2 revenues of $43.2 billion, slightly above consensus despite a 0.4% YoY decline driven by Medicaid membership attrition. Analysts express concerns over ongoing Medicaid margin... 
Via Benzinga
Healthcare Investors Bet On Easier Medicare Rules Under Potential Trump Administration
Investors expect Trump to ease Medicare Advantage regulations if he wins another term. This could lead to renewed merger talks among health insurers. 
Via Benzinga
Topics Government
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical... 
Via Benzinga
Topics Cannabis
What Analysts Are Saying About Cigna Group Stock
Via Benzinga
Here's How Much $1000 Invested In Cigna Group 5 Years Ago Would Be Worth Today
Via Benzinga
3 of the Best Stock Buybacks So Far in 2024
S&P 500 companies made nearly $240 billion in stock buybacks in the first quarter, 9.9% higher than a year ago. Here are three of the best. 
Via InvestorPlace
Topics Stocks
FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth
The FTC's report reveals how major PBMs like UnitedHealth, CVS, and Cigna influence drug prices, impacting small pharmacies and consumers. 
Via Benzinga
When you look at NYSE:CI, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Investors should take notice ofTHE CIGNA GROUP (NYSE:CI)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Why Walgreens Boots Alliance Plunged in June
Walgreens' results went from bad to worse in June. 
Via The Motley Fool
Investors should take note of NYSE:CI, a growth stock that remains attractively priced.
Looking for growth without the hefty price tag? Consider THE CIGNA GROUP (NYSE:CI). 
Via Chartmill
Despite its growth, NYSE:CI remains within the realm of affordability.
In the world of growth stocks, NYSE:CI shines as a value proposition. 
Via Chartmill
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,700 Today
Via Benzinga
Down Over 60%, Is Walgreens Boots Alliance a Bad-News Buy?
After falling a long way, the pharmacy stock is trading at a surprisingly low valuation. 
Via The Motley Fool
Elevance Stock Elevated On Excellent Marketing Execution
Elevance stock boasts a 92 EPS Rating out of 99. It has an 86 Composite Rating and a B+ Accumulation/Distribution Rating. 
Via Investor's Business Daily
Cigna's Specialty Pharmacy Leadership Expected to Drive Long-Term EPS Growth, Analyst Says
Piper Sandler has initiated coverage on Cigna, highlighting its strong position in the specialty pharmacy market and robust growth in the Cigna Healthcare and Evernorth Health Services businesses. 
Via Benzinga
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for June 2024
Commanding incredible relevancy, these strong buy healthcare stocks should be on every investor’s watch list. 
Via InvestorPlace
NYSE:CI appears to be flying under the radar despite its strong fundamentals.
For those who appreciate value investing, THE CIGNA GROUP (NYSE:CI) is a compelling option with its solid fundamentals. 
Via Chartmill
10 Value Stocks With Low Debt And Strong Growth
One of the problems we are facing as a value investor is an extremely high stock market and an aberrantly long-running bull market. It’s one of the longest in recorded history. 
Via Talk Markets
Combatting the Loneliness Epidemic: The Role of Muah AI in Providing Emotional Support
Combatting the Loneliness Epidemic: The Role of Muah AI in Providing Emotional Support 
Via News Direct
Topics Artificial Intelligence
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.